Saxenda Injections for Weight Loss: the Facts Before You Decide

Is Saxenda still the right starting point for weight-loss injections?

Saxenda was, for several years, the most widely recognised injectable weight-loss medicine in the UK. That position has shifted. Wegovy (semaglutide 2.4mg, once weekly) was approved by the MHRA for weight management in 2021 and is recommended by NICE under TA875. Mounjaro (tirzepatide, once weekly) received its UK weight-management licence in 2023 and is now recommended by NICE under TA1026, published December 2024. Both have reported average weight reductions in clinical trials that substantially exceed liraglutide's figures at 56 weeks. The STEP 1 trial of semaglutide, published in the New England Journal of Medicine, found an average body-weight reduction of around 15% over 68 weeks at the 2.4mg maintenance dose. Tirzepatide's SURMOUNT-1 trial showed around 20–21% average reduction at the highest dose.

None of that means Saxenda is ineffective. For patients who tolerated it well, or who started it before the newer medicines became widely available, it remains a licensed treatment. The question most people typing "saxenda weight loss injections" into a search engine are really asking is: should I start this, or is something else better suited to me? That is a clinical decision, not a search-engine one. If you want to understand the broader landscape of weight loss injections available in the UK, that page covers the category in full.

Who Saxenda is licensed for, and where the eligibility overlaps with newer medicines

The licensed eligibility criteria for Saxenda mirror those of Mounjaro and Wegovy closely: adults with a BMI of 30 or above, or a BMI of 27 or above with at least one weight-related condition such as type 2 diabetes, hypertension, high cholesterol or obstructive sleep apnoea. Lower BMI thresholds can apply for some ethnic backgrounds under UK clinical guidance. Treatment should be used alongside a reduced-calorie diet and increased physical activity, and continued only if meaningful weight loss is achieved, typically at least 5% of starting body weight after 12 weeks on the maintenance dose.

On the NHS, access to Saxenda falls under specialist weight management services. Waiting lists are long in most areas. Private prescribing is possible through a registered pharmacy, provided a GPhC-registered prescriber has reviewed your medical history and confirmed suitability. If you are trying to work out whether your BMI and health history put you in range for any licensed weight-loss injection, the eligibility criteria for weight-loss injections page walks through each medicine's thresholds side by side. BMI alone never determines approval, the prescriber assesses the full clinical picture.

One practical note on Saxenda's daily injection schedule: unlike the once-weekly pens used for tirzepatide and semaglutide, liraglutide requires an injection every day, titrated from 0.6mg upward over five weeks to the 3mg maintenance dose. Some patients find a daily routine easier to remember; others find once-weekly far more convenient. That preference matters for long-term adherence, and it is worth raising with whoever is reviewing your case. You can read more about how the mechanics of weight-loss injections differ across medicines before your consultation.

Side effects, safety and what a GLP-1 injection actually feels like to use

Saxenda shares the GLP-1 class's characteristic side-effect profile. Nausea is the most commonly reported complaint, particularly during the dose-escalation phase. Diarrhoea, constipation, vomiting, indigestion and headache are also frequently reported. For most people these settle within a few weeks as the body adjusts. The NHS medicines pages for GLP-1 treatments set out the full side-effect lists alongside practical advice on managing them.

Pancreatitis is a rare but serious risk across the GLP-1 class. Severe, persistent abdominal pain that radiates to the back (with or without vomiting) warrants urgent medical attention and should not be waited out. The MHRA reinforced this guidance for all GLP-1 medicines in January 2026. Anyone on any weight-loss injection should also know about the Yellow Card scheme, which lets patients report suspected side effects directly to the MHRA. A dedicated sharps bin matters too: used needles need proper disposal, and a 1-litre sharps container is the practical option for home use.

Safety credentials of the pharmacy supplying any injectable medicine matter considerably. Fake or substandard weight-loss pens have caused harm in the UK; the MHRA has made large seizures of counterfeit injectable medicines from online sellers. Before ordering anything injectable online, check the supplier on the GPhC pharmacy register. Any seller offering prescription medicines without requiring a clinical assessment is operating outside UK law.

What is available instead, and how to move forward

Saxenda is not a medicine nume dispenses. The weight-loss injections we prescribe are Mounjaro (tirzepatide) and Wegovy (semaglutide), both of which hold current MHRA licences for weight management and both of which have trial data showing greater average weight reduction than liraglutide. A helpful comparison of the broader Mounjaro injection for weight loss covers what tirzepatide's clinical profile looks like in practice. For anyone curious about how different injectable medicines compare on results, the Saxenda before and after page puts the liraglutide evidence alongside newer figures so you can read them together. For context on what private weight-loss injections typically cost in the UK and what to check before paying, the guide to buying weight-loss injections safely covers the key questions. If you are ready to find out whether Mounjaro or Wegovy suits your situation, a free consultation with our prescribing team is the next step. A real clinician reads every submission the same day, not software, not an automated triage queue.